Quotient Sciences Appoints Thierry Van Nieuwenhove as CEO

Read Now

Quotient Sciences featured in Drug Development & Delivery's Outsourcing Formulation Development & Manufacturing Special Feature

Dr. Sarah Stevens, Quotient Sciences' VP of Drug Development Sciences, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one or­ganization, in Drug Development & Delivery's Special Feature Report entitled: "Outsourcing Formulation Development & Manufacturing: Meeting Demand for Biologics & Specialty Drugs"

Quotient Sciences: Combining Development Activities Saves Time

For the past decade, Quotient Sci­ences has created a delivery platform that integrates drug product and clin­ical testing activities to achieve pro­gram acceleration. To support this further, Quotient Sciences recently acquired Ar­cinova, the UK-based CDMO, be­cause of its expertise and capability in early-stage drug substance and bio­analysis work.

"We see a great opportunity for investing in and integrating drug sub­stance services into our existing drug product and clinical testing platform," says Sarah Stevens, Vice President of Drug Development Sciences, Quotient Sciences.

Drug substance manufacturing often sits on the critical path in early development with drug product man­ufacturing and clinical trial initiation routinely suffering from late API sup­ply, she says. As one of the major causes of project delays, it is important for biotech companies to work closely with API manufacturers early in the de­velopment process to ensure the drug substance is not only supplied on time but that potential formulation or downstream challenges have also been identified or flagged up front.

"The investment in this capability will enable the integration of drug substance, drug product, and clinical testing capabilities – all under one or­ganization with a single Project Man­agement function," she says.

In this environment, chemists work hand-in-hand with formulators and biopharmaceutics experts, sharing in­formation about the properties of the molecule and troubleshooting formu­lation strategies. Drug product manu­facturing scientists work alongside clinical teams, ensuring that the needs of the clinical trial and patient groups are met.

She says: "This will cut through more industry silos by combining a range of drug development capabili­ties, creating additional timeline sav­ings for our clients and ultimately helping to get new drug molecules to patients, faster."

Access the full article here: